90. Retinitis pigmentosa Clinical trials / Disease details
Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03584165 (ClinicalTrials.gov) | June 4, 2018 | 29/6/2018 | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects With Choroideremia Previously Treated With Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects With X-Linked Retinitis Pigmentosa Previously Treated With Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study | Choroideremia;X-Linked Retinitis Pigmentosa | Genetic: BIIB111;Genetic: BIIB112 | NightstaRx Ltd, a Biogen Company | NULL | Enrolling by invitation | 10 Years | N/A | Male | 440 | Phase 3 | United States;Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom |